AbbVie’s mega-blockbuster Humira is facing biosimilar competition, but another patent licensing agreement, this time with Mylan, sees the company securing exclusivity through to 2023 in the US.
How to promote new therapies for neonates though education and extended exclusivity
from Outsourcing-Pharma.com
Novartis seeks out-licensing partners as it exits antibiotics R&D
from in-PharmaTechnologist.com
FoxBio: $10m JV launched to target age-related disease
from Outsourcing-Pharma.com
US FDA approves first treatment for smallpox to protect against bioterrorism
from in-PharmaTechnologist.com
Novartis selects French CDMO to make CAR T-cell therapies
Cell & Gene Therapies
Selexis and Symphogen expand partnership to progress two mAbs
Pipelines
Pluristem brings in Thermo Fisher to ‘transform cell therapy manufacturing’
Cell & Gene Therapies
Forbion looks to take advantage of 'undersupply' of capital to European life sciences
Pipelines
